ARCHIVES

Control-Arm CML Patients In Phase III Gleevec Study Allowed To Switch.

This article is from The Cancer Letter archive.

Vol. 28 No. 04 | January 25, 2002

Download PDF Visit The Full Archive

Related Articles

Senators Urge Grassroots Support For Health Research Fund Legislation

May 16, 1997

In Brief: Karmanos Institute Names Four To Faculty; $1.5M Donated To Kaplan Cancer Center

September 11, 1998

Harkin, Specter Propose A $5.2-Billion Supplement For NIH. Senate Report Says NIH Funding At “Crisis Point.”

July 18, 2008

Watson Steps Down As Chancellor at Cold Spring Harbor Laboratory.

October 26, 2007

Tamoxifen Listed By IARC Report As Carcinogen CTRF Seeks Applicants

March 1, 1996

DCT board Okays Recompetition of Clinical Trials Contracts

October 29, 1993